Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jul;142(1):3-13.
doi: 10.1111/ane.13246. Epub 2020 Apr 14.

Epilepsy treatment gap in Sub-Saharan Africa: Meta-analysis of community-based studies

L F Owolabi  1 , S D Owolabi  2 , B Adamu  3 , A M Jibo  4 , I D Alhaji  1
Affiliations
Meta-Analysis

Epilepsy treatment gap in Sub-Saharan Africa: Meta-analysis of community-based studies

L F Owolabi et al. Acta Neurol Scand. 2020 Jul.

Abstract

Objective: To evaluate the prevalence, highlight the variation and determine the trend over time, of epilepsy treatment gap (ETG) in Sub-Saharan Africa (SSA).

Methods: We systematically searched PubMed, MEDLINE, Embase, ISI databases, and African Journal Online (AJOL). We determined the pooled prevalence estimate of ETG and the degree of heterogeneity in the region. Further subgroup analysis by sub-region, settlement setting, and cutoff adopted for active epilepsy in the studies was carried out. Meta-regression technique was also used to determine the trend of the ETG magnitude over time.

Results: Twenty-three studies from SSA met the inclusion criteria. We found a high level of discordance among the studies that were included. Collectively, the estimated ETG was 68.5% (95% CI: 59.5%-77.5%). On subgroup analysis, the prevalence of the ETG was 67% (95% CI: 52%, 83%) in the Western, 68% (95% CI: 56%, 80%) in the Eastern, and 63% (95% CI: 53%, 73%) in the Southern Africa sub-regions. On stratified analysis based on 1-year, 5-year, and 2-year cutoffs for definition of active epilepsy, the prevalence figures for the ETG were 71% (95% CI: 56%, 85%), 55% (95% CI: 33%, 77%), and 57% (95% CI: 43%, 71%), respectively. Meta-regression result suggested that the prevalence of the ETG decreases by approximately by 0.006 per year.

Conclusion: The study showed a high prevalence of ETG, higher than the average for resource poor countries, and twice in rural compared with urban settlements in SSA.

Keywords: Sub-Saharan Africa; epilepsy; magnitude; treatment gap; trend.

PubMed Disclaimer

References

REFERENCES

    1. WHO.United Nations high-level meeting on noncommunicable disease prevention and control. WHO. [cited 2019 Jan 4]. Available from: http://www.who.int/nmh/events/un_ncd_summit2011/en/
    1. Leonardi M, Ustun TB. The global burden of epilepsy. Epilepsia. 2002;43(Suppl. 6):21-25.
    1. Mbuba CK, Ngugi AK, Newton CR, Carter JA. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes and intervention strategies. Epilepsia. 2008;49:1491-1503.
    1. Beghi E, Giussani G, Nichols E, et al. Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:357-375.
    1. WHO. Atlas: Epilepsy Care in the World 2005. WHO. [cited 2019 Jan 4]. Available from: https://www.who.int/mental_health/publications/atlas_epilepsy_care_2005/en/